Key Takeaways:
- Reports Q1 obesity care sales growth of 22% at constant exchange rates
- Raises full-year 2026 financial outlook after beating Q1 estimates
- Faces rising competition from Eli Lilly and new generic semaglutide in India
Back
Novo Nordisk lifts 2026 outlook after 22% sales growth
Novo Nordisk raised its 2026 outlook after reporting first-quarter obesity care sales grew 22 percent, even as it faces intensifying competition in the booming weight-loss drug market.
"Wegovy is driving a strong start to 2026 for Novo Nordisk, led by the rapid adoption of the Wegovy pill,” Mike Doustdar, president and CEO of Novo Nordisk, said in a statement.
The Danish drugmaker’s total sales reached DKK 96.8 billion in the first quarter, beating analyst estimates for revenue and earnings. The company's new Wegovy pill, launched in the US in January 2026, has already crossed two million prescriptions.
The results highlight the soaring demand for GLP-1 therapies that pushed the global market estimate to over $70 billion for 2026. However, the company's long-term performance will depend on defending its market share against rival Eli Lilly and a new wave of lower-priced generics.
The company acknowledged the changing landscape, flagging the launch of generic versions of its key semaglutide molecule by more than a dozen companies in India during the first quarter. Novo Nordisk said it expects to experience an adverse impact on sales from this loss of exclusivity.
“The real challenge lies in the limited understanding of obesity as a disease. Our role has been to drive clarity and standardisation,” Vikrant Shrotriya, Managing Director of Novo Nordisk India, said, noting the company's focus on medical education.
The guidance raise signals strong confidence in its Wegovy and Ozempic franchises for now. Investors will be closely watching for any impact from generic entry in India and sales figures from Eli Lilly's competing drugs in the upcoming second-quarter report.
This article is for informational purposes only and does not constitute investment advice.
[1] Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?[2] Earnings live updates: Klarna stock surges, Cisco announces thousands of layoffs[3] Earnings live updates: Cisco announces 4,000 layoffs as Q3 earnings beat amid 'broad-based demand'[4] Why Novo Nordisk is cautioning against the sale of semaglutide generics in India[5] Is Novo Nordisk's Rebound for Real--or Just a Head Fake?
